2ND ADVANCED COURSE ON THE PHARMACOLOGICAL TREATMENT OF DRUG RESISTANT EPILEPSIES (DRE): FROM RARE TO COMMON EPILEPSIES
Friday, 8th November
DEFINITION AND EPIDEMIOLOGY
16:15 h - 16:30 h
Welcome and Introduction
Jose M Serratosa Fernández. Hospital Universitario Fundación Jiménez Díaz. Madrid, Spain Manuel Toledo Argany. Hospital Universitario Vall d'Hebron. Barcelona, Spain Torbjörn Tomson. Department of Clinical Neuroscience, Karolinska Institutet. Stockholm, Sweden Bernhard Steinhoff. Neurology and Clinical Neurophysiology, University of Freiburg. Kork Epilepsy Center, Kehl-Kork, Germany
16:30 h - 17:00 h
Concept, Epidemiology and social impact of DRE
Eugen Trinka. Paracelsus University. Salzburg, Austria
17:00 h - 17:30 h
Other impact of DRE: Mortality and SUDEP
Torbjörn Tomson. Department of Clinical Neuroscience, Karolinska Institutet. Stockholm, Sweden
17:30 h - 18:00 h
Pseudo-DRE: Concept and diagnosis
Torbjörn Tomson. Department of Clinical Neuroscience, Karolinska Institutet. Stockholm, Sweden
18:00 h - 19:00 h
Cases: Difficult to diagnose DRE
Jose M Serratosa Fernández. Hospital Universitario Fundación Jiménez Díaz. Madrid, Spain Torbjörn Tomson. Department of Clinical Neuroscience, Karolinska Institutet. Stockholm, Sweden Bernhard Steinhoff. Neurology and Clinical Neurophysiology, University of Freiburg. Kork Epilepsy Center, Kehl-Kork, Germany
Pharmacokinetic interactions between ASMs used in polytherapy
Cecilie Johannessen Landmark. Oslo University Hospital, Oslo, Norway
10:30 h - 11:00 h
Rational polytherapy V.2024. Interactions of third generation ASM.
Andres M Kanner. University of Miami Miller School of Medicine. USA
11:00 h - 11:30 h
Overtreatment vs therapeutic nihilism
Bernhard Steinhoff. Neurology and Clinical Neurophysiology, University of Freiburg. Kork Epilepsy Center, Kehl-Kork, Germany
11:30 h - 12:30 h
Cases: Polytherapy and interactions
Bernhard Steinhoff. Neurology and Clinical Neurophysiology, University of Freiburg. Kork Epilepsy Center, Kehl-Kork, Germany Andres M Kanner. University of Miami Miller School of Medicine. USA Cecilie Johannessen Landmark. Oslo University Hospital, Oslo, Norway
Chairman: Manuel Toledo Argany
12:30 h - 13:00 h
Symposium 1
13:00 h - 14:00 h
Lunch
17:30 h - 18:00 h
Symposium 2 - Angelini Pharma
FUTURE ASMs AND THERAPIES
14:00 h - 14:30 h
ASMs close to launching and future strategies
Meir Bialer. Institute for Drug Research, School of Pharmacy and David R. Bloom Centre for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. Jerusalem, Israel
14:30 h - 15:00 h
Advanced therapies
Jose M Serratosa Fernández. Hospital Universitario Fundación Jiménez Díaz. Madrid, Spain
15:00 h - 15:30 h
RNA therapies
Felix Rosenow. Epilepsy Center Frankfurt Rhine-Main. Center of Neurology and Neurosurgery, Goethe-University Frankfurt. Frankfurt, Germany
15:30 h - 16:00 h
Break
IDIOPATHIC GENERALIZED EPILEPSIES (IGEs)
16:00 h - 16:30 h
Drug resistant IGEs: clinical characteristics
Javier Salas Puig. Hospital Universitario Vall d'Hebron. Barcelona, Spain
16:30 h - 17:00 h
Treatment of drug resistant IGEs
Guido Rubboli. Institute of Clinical Medicine, University of Copenhagen, Danish Epilepsy Center, Dianalund, Denmark
Sunday, 10th November
DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs)
08:30 h - 09:00 h
Clinical characteristics of the main types of DEEs
Elena Gardella. Danish Epilepsy Center and University of Southern Denmark. Dianalund, Denmark
09:00 h - 09:30 h
Treatment of Dravet disease and Lennox-Gastaut syndrome
Stephan Auvin. Robert Debré Hospital, Public Hospital Network of Paris. Paris, France
09:30 h - 10:00 h
Treatment of other DEEs: CDKL5, KNQ2, SCN8A, SCN2A, DEPDC5
10:00 h - 10:30 h
Break
10:30 h - 11:30 h
Cases: DEEs
Stephan Auvin. Robert Debré Hospital, Public Hospital Network of Paris. Paris, France Elena Gardella. Danish Epilepsy Center and University of Southern Denmark. Dianalund, Denmark
Chairman: Manuel Toledo Argany
11:30 h - 12:00 h
Symposium 3 - UCB Pharma
SPECIAL LECTURE
12:00 h - 12:15 h
Outcome measures in DRE clinical trials
Jacqueline French. NYU Grossman School of Medicine. New York, USA
12:15 h - 12:45 h
Comprehensive evaluation test
12:45 h - 13:00 h
Conclusions
Jose M Serratosa Fernández. Hospital Universitario Fundación Jiménez Díaz. Madrid, Spain Manuel Toledo Argany. Hospital Universitario Vall d'Hebron. Barcelona, Spain Torbjörn Tomson. Department of Clinical Neuroscience, Karolinska Institutet. Stockholm, Sweden Bernhard Steinhoff. Neurology and Clinical Neurophysiology, University of Freiburg. Kork Epilepsy Center, Kehl-Kork, Germany
